The approval of medicines called second-generation antipsychotics has allowed major depressive disorder (MDD) and other conditions linked to it to be treated. A person with MDD is usually prescribed ...

The approval of medicines called second-generation antipsychotics has allowed bipolar I and other associated conditions to be treated. A person with bipolar I disorder can go through various mood ...

Vraylar (cariprazine) is a powerful antipsychotic medication that is approved by the Food and Drug Administration (FDA) to treat schizophrenia, bipolar disorder, and major depressive disorder (MDD).

AbbVie ABBV announced that the FDA has approved Vraylar (cariprazine) for the adjunctive treatment of patients with major depressive disorder (MDD). Vraylar is presently approved for treating ...

With its latest authorization, Vraylar has gained access to a large market. It can now be used as an add-on treatment for major depressive disorder. The indication could generate $400 million in ...

DUBLIN and BUDAPEST, Hungary, Sept. 17, 2015 /PRNewswire/ -- Allergan plc (NYSE: AGN) and Gedeon Richter Plc. announced today that the U.S. Food and Drug Administration (FDA) has approved VRAYLAR™ ...

Please provide your email address to receive an email when new articles are posted on . Allergan recently announced that Vraylar, a once-daily oral atypical antipsychotic, is now available by ...

AbbVie’s antipsychotic Vraylar could get a major boost from a potential expansion into depression. But like some other late-stage contenders, the drug’s clinical results fell short of a home run.

Allergan plcAGN, along with partner Gedeon Richter, announced positive top-line results from a second pivotal phase III study on its schizophrenia drug Vraylar. The study evaluated Vraylar ...

It’s not known whether Vraylar is safe to take while pregnant or breastfeeding. Certain factors, including the risks of not treating your condition during pregnancy, may determine whether you should ...

NEW ORLEANS -- Adjunctive cariprazine (Vraylar) was linked with a reduction in depressive symptoms for patients with major depressive disorder (MDD), who had an inadequate response to current therapy, ...